EVH Quote, Financials, Valuation and Earnings

Astrana Health, Inc. has a net margin of -4.35% compared to Evolent Health, Inc.'s net margin of 0.11%. Evolent Health, Inc.'s return on equity of -13.6% beat Astrana Health, Inc.'s return on equity of 1.85%.

Evolent Health, Inc. has a consensus price target of $8.50, signalling upside risk potential of 204.66%. On the other hand Astrana Health, Inc. has an analysts' consensus of $35.6667 which suggests that it could grow by 79.59%. Given that Evolent Health, Inc. has higher upside potential than Astrana Health, Inc., analysts believe Evolent Health, Inc. is more attractive than Astrana Health, Inc..

Evolent Health, Inc. has a beta of 0.269, which suggesting that the stock is 73.123% less volatile than S&P 500. In comparison Astrana Health, Inc. has a beta of 0.904, suggesting its less volatile than the S&P 500 by 9.555%.

Evolent Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Astrana Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evolent Health, Inc. pays 32.59% of its earnings as a dividend. Astrana Health, Inc. pays out -- of its earnings as a dividend. Evolent Health, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Evolent Health, Inc. quarterly revenues are $479.5M, which are smaller than Astrana Health, Inc. quarterly revenues of $956M. Evolent Health, Inc.'s net income of -$20.9M is lower than Astrana Health, Inc.'s net income of $1.1M. Notably, Evolent Health, Inc.'s price-to-earnings ratio is -- while Astrana Health, Inc.'s PE ratio is 104.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evolent Health, Inc. is 0.16x versus 0.34x for Astrana Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Omnicell, Inc. has a net margin of -4.35% compared to Evolent Health, Inc.'s net margin of -0.65%. Evolent Health, Inc.'s return on equity of -13.6% beat Omnicell, Inc.'s return on equity of 0.17%.

Evolent Health, Inc. has a consensus price target of $8.50, signalling upside risk potential of 204.66%. On the other hand Omnicell, Inc. has an analysts' consensus of $57.43 which suggests that it could grow by 42.64%. Given that Evolent Health, Inc. has higher upside potential than Omnicell, Inc., analysts believe Evolent Health, Inc. is more attractive than Omnicell, Inc..

Evolent Health, Inc. has a beta of 0.269, which suggesting that the stock is 73.123% less volatile than S&P 500. In comparison Omnicell, Inc. has a beta of 0.776, suggesting its less volatile than the S&P 500 by 22.402%.

Evolent Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Omnicell, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evolent Health, Inc. pays 32.59% of its earnings as a dividend. Omnicell, Inc. pays out -- of its earnings as a dividend. Evolent Health, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Evolent Health, Inc. quarterly revenues are $479.5M, which are larger than Omnicell, Inc. quarterly revenues of $314M. Evolent Health, Inc.'s net income of -$20.9M is lower than Omnicell, Inc.'s net income of -$2M. Notably, Evolent Health, Inc.'s price-to-earnings ratio is -- while Omnicell, Inc.'s PE ratio is 931.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evolent Health, Inc. is 0.16x versus 1.57x for Omnicell, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pacific Health Care Organization, Inc. has a net margin of -4.35% compared to Evolent Health, Inc.'s net margin of 14.05%. Evolent Health, Inc.'s return on equity of -13.6% beat Pacific Health Care Organization, Inc.'s return on equity of 11.97%.

Evolent Health, Inc. has a consensus price target of $8.50, signalling upside risk potential of 204.66%. On the other hand Pacific Health Care Organization, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Evolent Health, Inc. has higher upside potential than Pacific Health Care Organization, Inc., analysts believe Evolent Health, Inc. is more attractive than Pacific Health Care Organization, Inc..

Evolent Health, Inc. has a beta of 0.269, which suggesting that the stock is 73.123% less volatile than S&P 500. In comparison Pacific Health Care Organization, Inc. has a beta of 0.126, suggesting its less volatile than the S&P 500 by 87.368%.

Evolent Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pacific Health Care Organization, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.10 per share. Evolent Health, Inc. pays 32.59% of its earnings as a dividend. Pacific Health Care Organization, Inc. pays out -- of its earnings as a dividend. Evolent Health, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Evolent Health, Inc. quarterly revenues are $479.5M, which are larger than Pacific Health Care Organization, Inc. quarterly revenues of $1.6M. Evolent Health, Inc.'s net income of -$20.9M is lower than Pacific Health Care Organization, Inc.'s net income of $223K. Notably, Evolent Health, Inc.'s price-to-earnings ratio is -- while Pacific Health Care Organization, Inc.'s PE ratio is 11.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evolent Health, Inc. is 0.16x versus 2.53x for Pacific Health Care Organization, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

WW International has a net margin of -4.35% compared to Evolent Health, Inc.'s net margin of -38.91%. Evolent Health, Inc.'s return on equity of -13.6% beat WW International's return on equity of --.

Evolent Health, Inc. has a consensus price target of $8.50, signalling upside risk potential of 204.66%. On the other hand WW International has an analysts' consensus of $1.10 which suggests that it could grow by 340.71%. Given that WW International has higher upside potential than Evolent Health, Inc., analysts believe WW International is more attractive than Evolent Health, Inc..

Evolent Health, Inc. has a beta of 0.269, which suggesting that the stock is 73.123% less volatile than S&P 500. In comparison WW International has a beta of 1.298, suggesting its more volatile than the S&P 500 by 29.755%.

Evolent Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. WW International offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evolent Health, Inc. pays 32.59% of its earnings as a dividend. WW International pays out -- of its earnings as a dividend. Evolent Health, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Evolent Health, Inc. quarterly revenues are $479.5M, which are larger than WW International quarterly revenues of $186.6M. Evolent Health, Inc.'s net income of -$20.9M is higher than WW International's net income of -$72.6M. Notably, Evolent Health, Inc.'s price-to-earnings ratio is -- while WW International's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evolent Health, Inc. is 0.16x versus 0.03x for WW International. Usually stocks with elevated PS ratios are considered overvalued.